Home > Riviste > Minerva Chirurgica > Fascicoli precedenti > Minerva Chirurgica 2015 Aprile;70(2) > Minerva Chirurgica 2015 Aprile;70(2):119-29

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

MINERVA CHIRURGICA

Rivista di Chirurgia


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,877


eTOC

 

REVIEW  


Minerva Chirurgica 2015 Aprile;70(2):119-29

lingua: Inglese

Looking into the “Garden of the Hesperides”: new drugs for hepatocellular carcinoma

Castañón Alvarez E. 1, 2, Giallombardo M. 2, 3, Gil-Bazo I. 1, Papadimitriou K. 4, Pauwels P. 5, 6, Peeters M. 4, 5, Rolfo C. 2, 5

1 Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain;
2 Phase I‑Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital, Edegem, Belgium;
3 Dipartimento di Biopatologia e Biotecnologie Mediche, Sezione di Biologia e Genetica, Università di Palermo, Palermo, Italy;
4 Oncology Department, Antwerp University Hospital, Edegem, Belgium;
5 Center of Oncological Research (CORE), Antwerp University, Wilrijk, Belgium;
6 Molecular Pathology Unit, Pathology Department, Antwerp University Hospital, Edegem, Belgium


PDF  


Advanced hepatocellular carcinoma remains an entity that is hard to approach therapeutically and has shown disappointing results in terms of survival. For many years, the only accepted option for this setting was the use of a multikinase inhibitor, sorafenib. Nevertheless, through the years, a deeper knowledge has arisen about how pathogenic pathways correlate with hepatocellular carcinoma. In this review, we provide an update of the most recent data regarding new agents under investigation and new possible targets for future treatments.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

christian.rolfo@uza.be